Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA)

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1-year target prices for Enanta Pharmaceuticals' stock. Their ENTA share price targets range from $14.00 to $87.00. On average, they expect the company's share price to reach $31.88 in the next year. This suggests a possible upside of 244.6% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of 2023. Since then, ENTA stock has decreased by 80.1% and is now trading at $9.25.
View the best growth stocks for 2023 here.

Enanta Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,510,000 shares, an increase of 12.7% from the October 31st total of 1,340,000 shares. Based on an average trading volume of 459,800 shares, the days-to-cover ratio is presently 3.3 days. Approximately 7.7% of the company's shares are sold short.
View Enanta Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.11) by $0.78. The biotechnology company had revenue of $18.93 million for the quarter, compared to analyst estimates of $17.93 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 52.23% and a negative net margin of 168.95%. During the same quarter in the previous year, the company posted ($1.27) earnings per share.

ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.97%), Northern Trust Corp (4.56%), Krensavage Asset Management LLC (3.49%), Assenagon Asset Management S.A. (3.00%), Acadian Asset Management LLC (2.61%) and Jacobs Levy Equity Management Inc. (1.64%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus and Yat Sun Or.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.